We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accuray TomoTherapy System Starts Cancer Treatment in Africa
Read MoreHide Full Article
Headquartered in Sunnyvale, CA, Accuray Inc. (ARAY - Free Report) recently announced that the Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria has finally initiated cancer treatment with the company’s flagship TomoTherapy system.
Furthermore, the Radiotherapy and Medical Oncology Center announced the purchase of the company’s CyberKnife M6 system, which is scheduled to be installed by 2018-end.
Notably, Accuray’s top-line growth is highly leveraged on CyberKnife and TomoTherapy system sales. Per management, with the combined availability of CyberKnife and TomoTherapy in one location, the Center will be able to provide ‘highly precise’ radiation therapy in Algeria.
The latest development has been realized in accordance with the postulates of the Algerian Cancer Plan 2015–2019 that aims to improve the quality of radiotherapy, ease out the registration procedure of appointments and focus exclusively on the safety of care in radiotherapy. In fact, TomoTherapy can deliver safe treatment to a wide range of tumor types while keeping the surrounding tissues healthy.
Stock Price & Estimate Revision Trend
Accuray has had an impressive run on the bourse on a year-to-date basis. The company gained roughly 7%, higher than the Zacks categorized Medical instruments sub-industry’s addition of almost 5%. Moreover, the current level compares favorably with the S&P 500’s return of 6% over the same time frame. This, together with a long-term expected earnings growth rate of 15%, instills confidence in investors.
Furthermore, the estimate revision for the stock has been favorable. The year has seen one estimate move north over the last two months, compared with no movement in the opposite direction. As a result, the full-year estimates narrowed down by a penny to a loss of 15 cents over the same time frame.
Driven by the bullish analyst sentiments, Accuray carries a Zacks Rank #2 (Buy), signifying probabilities of outperformance in the near term.
Bottom line
We are highly upbeat about the bountiful opportunities in the radiotherapy market of the Middle East and Africa. A research report by MarketDataForecast projects that the niche markets are set to reach a worth of $650.29 million by 2021, growing at a CAGR of 5.8%.
However, both TomoTherapy and CyberKnife systems involve significant capital spending, which many healthcare providers are reluctant to spend, courtesy of the sluggish macro-economic conditions. Both the systems have long sales and implementation cycles, escalating the concerns for Accuray.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 52.9%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a stellar one-year return of roughly 18.3%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last 3–5 years of actual earnings) of almost 22%.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Accuray TomoTherapy System Starts Cancer Treatment in Africa
Headquartered in Sunnyvale, CA, Accuray Inc. (ARAY - Free Report) recently announced that the Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria has finally initiated cancer treatment with the company’s flagship TomoTherapy system.
Furthermore, the Radiotherapy and Medical Oncology Center announced the purchase of the company’s CyberKnife M6 system, which is scheduled to be installed by 2018-end.
Notably, Accuray’s top-line growth is highly leveraged on CyberKnife and TomoTherapy system sales. Per management, with the combined availability of CyberKnife and TomoTherapy in one location, the Center will be able to provide ‘highly precise’ radiation therapy in Algeria.
The latest development has been realized in accordance with the postulates of the Algerian Cancer Plan 2015–2019 that aims to improve the quality of radiotherapy, ease out the registration procedure of appointments and focus exclusively on the safety of care in radiotherapy. In fact, TomoTherapy can deliver safe treatment to a wide range of tumor types while keeping the surrounding tissues healthy.
Stock Price & Estimate Revision Trend
Accuray has had an impressive run on the bourse on a year-to-date basis. The company gained roughly 7%, higher than the Zacks categorized Medical instruments sub-industry’s addition of almost 5%. Moreover, the current level compares favorably with the S&P 500’s return of 6% over the same time frame. This, together with a long-term expected earnings growth rate of 15%, instills confidence in investors.
Furthermore, the estimate revision for the stock has been favorable. The year has seen one estimate move north over the last two months, compared with no movement in the opposite direction. As a result, the full-year estimates narrowed down by a penny to a loss of 15 cents over the same time frame.
Driven by the bullish analyst sentiments, Accuray carries a Zacks Rank #2 (Buy), signifying probabilities of outperformance in the near term.
Bottom line
We are highly upbeat about the bountiful opportunities in the radiotherapy market of the Middle East and Africa. A research report by MarketDataForecast projects that the niche markets are set to reach a worth of $650.29 million by 2021, growing at a CAGR of 5.8%.
However, both TomoTherapy and CyberKnife systems involve significant capital spending, which many healthcare providers are reluctant to spend, courtesy of the sluggish macro-economic conditions. Both the systems have long sales and implementation cycles, escalating the concerns for Accuray.
Other Key Picks
Other top-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 52.9%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a stellar one-year return of roughly 18.3%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last 3–5 years of actual earnings) of almost 22%.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>